An interventional study of 660 nm Visible Red Light and 850 nm Near-Infrared Light in Insomnia, sponsored by National Health Research Institutes, Taiwan. Not yet recruiting. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by National Health Research Institutes, Taiwan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background: Insomnia is a prevalent and growing public health issue, with one in three adults affected globally and one in five Taiwanese adults reporting significant sleep disturbances. Long-term use of sedative-hypnotic medications remains common in Taiwan despite clinical guidelines recommending short-term use only, contributing to adverse outcomes such as impaired sleep architecture, cognitive deficits, and elevated dementia risk. Non-pharmacological interventions-particularly light-based therapies-offer promising alternatives but existing bright-light therapy is limited by melatonin suppression and the need for precise daytime timing. Recent advances in photobiomodulation (PBM) suggest that red and near-infrared light, which do not suppress melatonin, may enhance sleep quality and support glymphatic clearance when applied during sleep. Preliminary findings from our prior NSTC-funded industry-academia project demonstrated that 850-nm PBM applied during sleep improved subjective sleep quality and sleep duration among older adults with insomnia who were not using hypnotics. Building on these results, the present study aims to evaluate whether sleep-period PBM can improve sleep quality, enhance daytime alertness and cognitive function, and reduce sedative-hypnotic medication use among adults with chronic insomnia who regularly use these medications.
Methods: This project will employ a four-week single-blind, randomized controlled trial with three parallel arms: (1) a 660-nm visible red-light group, in which participants will wear the light device for one hour before bedtime each night; (2) an 850 ± 10-nm near-infrared light group, in which participants will wear the light device for one hour before bedtime each night, and (3) a sham control group using an inactive 630-nm red-light device. We will develop a wearable prototype that has undergone engineering validation. A total of 90 adults with chronic insomnia who use sedative-hypnotic medications on at least four days per week will be recruited and randomly assigned in a 1:1:1 ratio to the three study groups. Participants will be instructed to wear the assigned device continuously at the cymba choncae. Outcome assessments will be conducted at baseline and week 4, and will be followed at the 12th week. Primary outcomes will include subjective sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI), frequency of hypnotic medication use, and objective sleep parameters assessed by actigraphy. Secondary outcomes will include daytime sleepiness assessed by the Karolinska Sleepiness Scale (KSS), mood symptoms assessed by the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI), and performance on the Psychomotor Vigilance Task (PVT).
Expected contributions: This study is expected to generate clinical evidence in Taiwan evaluating nighttime PBM for insomnia in hypnotic-using populations, address the unmet need for portable, home-based, non-pharmacological sleep interventions, and support future commercialization of a sleep-compatible light therapy device. Results will inform device optimization, regulatory approval strategies, and market expansion efforts in the growing global sleep-health industry.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
This study's planned enrollment of 90 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Browse Sleep Initiation and Maintenance Disorders studies →National Health Research Institutes, Taiwan is the lead sponsor of 129 studies on the registry; 31 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive 660 nm visible red light before bedtime for 1 hour per night for 4 consecutive weeks. The light is delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 2.0 ± 0.2 mW/cm².
Device: 660 nm Visible Red Light
Participants will receive 850 ± 10 nm near-infrared light before bedtime for 1 hour per night for 4 consecutive weeks. The light is delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 12.5 ± 1.25 mW/cm².
Device: 850 nm Near-Infrared Light
Participants will receive 630 nm visible red light as a sham comparator before bedtime for 1 hour per night for 4 consecutive weeks.
Device: 630 nm Sham Control
Participants will receive 660 nm visible red light before bedtime for 1 hour per night for 4 consecutive weeks. The light will be delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 2.0 ± 0.2 mW/cm².
Participants will receive 850 ± 10 nm near-infrared light before bedtime for 1 hour per night for 4 consecutive weeks. The light will be delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 12.5 ± 1.25 mW/cm².
Participants will receive 630 nm visible red light as a sham comparator before bedtime for 1 hour per night for 4 consecutive weeks. The light will be delivered using a wearable light device.
Sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is used to assess sleep quality. The PSQI consists of seven components, each scored from 0 to 3, with a total score ranging from 0 to 21. Higher scores indicate poorer sleep quality.
Time frame: baseline, week 4, and week 12
Sedative-hypnotic medication use frequency
The frequency of sedative-hypnotic medication use will be assessed on a weekly basis to evaluate changes in medication use following the intervention.
Time frame: baseline, week 5, and week 12
Actigraphy-derived sleep parameters
Sleep parameters will be assessed using a wrist-worn actigraphy device. The measured parameters include average sleep duration, sleep onset latency, wake after sleep onset, and sleep efficiency.
Time frame: baseline and week 5
Daytime sleepiness
Daytime sleepiness will be assessed using the Karolinska Sleepiness Scale (KSS).
Time frame: baseline, week 5, and week 12
Psychomotor vigilance performance
Psychomotor vigilance performance will be assessed using a 3-minute psychomotor vigilance test (PVT) administered via smartphone. Outcomes include the number of lapses, mean reaction time, error number, reciprocal mean reaction time, and the fastest and slowest 10% reaction times.
Time frame: baseline and week 5
Heart rate variability
Heart rate variability (HRV) will be assessed to evaluate autonomic nervous system activity. Frequency-domain measures will include total power (TP), very low frequency (VLF), low frequency (LF), high frequency (HF), LF/HF ratio, LF%, and HF%.
Time frame: baseline and week 5
Sleep chronotype and sleep timing
Sleep chronotype and sleep timing will be assessed using the Munich Chronotype Questionnaire (MCTQ), including sleep timing preference, bedtime, and wake-up time.
Time frame: baseline, week 5, and week 12
Depressive symptoms
Depressive symptoms will be assessed using the Beck Depression Inventory-II (BDI-II).
Time frame: baseline, week 5, and week 12
Anxiety symptoms
Anxiety symptoms will be assessed using the Beck Anxiety Inventory (BAI).
Time frame: baseline, week 5, and week 12
Sedative-hypnotic dependence severity
Severity of sedative-hypnotic dependence will be assessed using the Severity of Dependence Scale (SDS).
Time frame: baseline, week 5, and week 12
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for May 2027, 4 months later.
Of 1,212 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 4 months is below that.
Counting every sponsor, half of 1,290 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
National Health Research Institutes, Taiwan →